The exercise period for Prostatype Genomic’s warrants of series 3 begins today

The exercise period for the warrants of series 3 (the "Warrants" or “TO3”) issued in connection with Prostatype Genomic AB ("Prostatype Genomics" or the "Company") rights issue of units announced on November 7, 2023 (the "Rights Issue") begins today and runs up to, and including, April 19, 2024. The exercise price is set at SEK 0.04 per share. Each Warrant entitles the holder to subscribe for one new share in Prostatype Genomics, and upon full exercise of the Warrants, the Company will receive approximately SEK 10.0 million before deductions for issuing costs.

“From today you can exercise the Warrants you received free of charge in our latest rights issue. We have since then made tremendous progress in the process of get market access in the US and we hope you will continue supporting Prostatype Genomics. We are well underway of making the Prostatype test accessible on the US market and expects to get reimbursement for our product in the end of the year. We have a very exciting year ahead of us”, says Fredrik Rickman (previously Persson), CEO Prostatype Genomics.

 

Summary of Warrant terms and conditions and key dates

Each Warrant entitles the holder to subscribe for one new share in Prostatype Genomics, and upon full exercise of the Warrants, the Company will receive approximately SEK 10.0 million before deductions for issuing costs. The exercise price was determined during the measurement period to 0.04 SEK per share, and the exercise period begins today and runs up to, and including, April 19, 2024. Note that an earlier deadline for exercise may apply to holders of Warrants held with a custodian. The last day of trading in the Warrants is April 17, 2024.

Complete terms and conditions for the Warrants are available on the Company's website and in the prospectus prepared by the Board of Directors of Prostatype Genomics in connection with the Rights Issue. The prospectus is available on the Company's and Carnegie Investment Bank AB (publ)'s respective websites. It is also available on the Swedish Financial Supervisory Authority's website www.fi.se.

Please find the summary of the offer attached.

Shares and share capital

Upon full exercise of the Warrants, the number of shares in Prostatype Genomics will increase by 249,921,984 shares to a total of 1,038,208,434 shares, and the share capital will increase by SEK 2,499,219.84 to SEK 10,382,084.34.

Exercise of warrants

Trustee-registered Warrants

If the warrant holder has their Warrants in a share depository, in an investment savings account (Sw. ISK), or an endowment insurance (Sw. Kapitalförsäkring) (trustee-registered holdings), subscription and payment will take place with the nominee, who will provide further instructions on the procedure for exercising the Warrants. Warrant holders should contact their nominee well in advance for further instructions regarding the exercise of Warrants, as different nominees have different processing times.

Directly registered Warrants (VP account)

Application is made via a subscription form available on Carnegie Investment Bank AB’s (publ) website www.carnegie.se and Prostatype Genomics' website www.prostatypegenomics.com. A pre-printed subscription form has been sent to directly registered warrant holders. Payment is made according to instructions on the application form. Both the subscription form and payment must be received by Carnegie Investment Bank AB (publ) by April 19, 2024.

Trading of Warrants

Holders who do not wish to exercise their warrants may sell them on Nasdaq First North Growth Market. The Warrants are traded until and including April 17, 2024, under the short name PROGEN TO3 and with ISIN SE0021150794. Warrants not exercised for subscription will expire without value.

Advisors

Prostatype Genomics mandated Penser By Carnegie and Advokatfirman Lindahl as financial and legal advisors respectively in connection with the Rights Issue.

 

For further information about Prostatype Genomics, please contact:

Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB

Telephone: +46 (0) 73 049 77 01.

e-mail: [email protected]

 

About Prostatype Genomics AB

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

 

Certified Advisor

Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, [email protected]

 

IMPORTANT INFORMATION

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Prostatype Genomics in any jurisdiction, neither from Prostatype Genomics nor from someone else.

 

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.

 

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. 

 

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.